- Home
- DLO vs SLNO Comparison
DLO vs SLNO Comparison
Compare DLO & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLO
- SLNO
- Stock Information
- Founded
- DLO 2013
- SLNO 1999
- Country
- DLO Uruguay
- SLNO United States
- Employees
- DLO N/A
- SLNO N/A
- Industry
- DLO Business Services
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DLO Consumer Discretionary
- SLNO Health Care
- Exchange
- DLO Nasdaq
- SLNO Nasdaq
- Market Cap
- DLO 4.6B
- SLNO 3.7B
- IPO Year
- DLO 2021
- SLNO 2014
- Fundamental
- Price
- DLO $14.37
- SLNO $65.72
- Analyst Decision
- DLO Buy
- SLNO Strong Buy
- Analyst Count
- DLO 9
- SLNO 9
- Target Price
- DLO $15.00
- SLNO $116.78
- AVG Volume (30 Days)
- DLO 2.4M
- SLNO 1.3M
- Earning Date
- DLO 11-12-2025
- SLNO 11-04-2025
- Dividend Yield
- DLO 3.49%
- SLNO N/A
- EPS Growth
- DLO 9.30
- SLNO N/A
- EPS
- DLO 0.48
- SLNO N/A
- Revenue
- DLO $863,482,000.00
- SLNO $32,656,999.00
- Revenue This Year
- DLO $38.48
- SLNO N/A
- Revenue Next Year
- DLO $26.72
- SLNO $181.30
- P/E Ratio
- DLO $30.54
- SLNO N/A
- Revenue Growth
- DLO 22.02
- SLNO N/A
- 52 Week Low
- DLO $7.61
- SLNO $41.50
- 52 Week High
- DLO $16.78
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- DLO 43.83
- SLNO 49.49
- Support Level
- DLO $14.84
- SLNO $66.12
- Resistance Level
- DLO $15.88
- SLNO $72.55
- Average True Range (ATR)
- DLO 0.71
- SLNO 3.58
- MACD
- DLO -0.12
- SLNO 0.23
- Stochastic Oscillator
- DLO 6.06
- SLNO 26.72
About DLO DLocal Limited
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.